Senior Manager, Program and Alliance Management

As Senior Manager of Program and Alliance Management you’ll report to the COO and play a key role in supporting our pipeline of AI enabled preclinical assets. You will work closely with program team leads to ensure effective management of our internal programs and will also be responsible for managing our alliances with external partners including Lilly and Genentech. 

• Develops and manages timelines,
• Works with the finance team to develop and maintain budgets,
• Proactively and creatively contributes to risk identification and mitigation planning,
• Supports cross-functional teams comprising members from diverse subject areas – including: biology, chemistry, CMC, and new product planning,
• Clearly communicates program status to internal company stakeholders including senior management,
• Contributes to a positive team environment that encourages trust, robust debate, and ensures clear transparent communications.

• Manages collaboration with key partners to ensure goals are met or exceeded.
• Coordinates activities of scientific and engineering teams working on the collaborations.
• Interfaces with alliance partner leadership and participate in steering committee meetings a appropriate.

• 5+ yrs successfully supporting programs as Program Manager. Experience with small molecules is ideal.
• Strong communicator with ability to synthesize complex information for a variety of audiences (e.g., senior management, board of directors, investors).
• PhD in a life science related field required.
• Strong understanding of the drug development process – especially for preclinical programs.
• Able to think critically and demonstrate troubleshooting and problem-solving skills.
• Ability to synthesize complex information and communicate comprehensively to the organization. 

Genesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases. 

Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and h Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50. 

Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.